Triple
T19992660
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | APOE ε3 allele |
E494101
|
entity |
| Predicate | consideredClinicalEffectOnAlzheimersDisease |
P47123
|
FINISHED |
| Object | neutral |
—
|
LITERAL FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: neutral | Statement: [APOE ε3 allele, consideredClinicalEffectOnAlzheimersDisease, neutral]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: consideredClinicalEffectOnAlzheimersDisease Context triple: [APOE ε3 allele, consideredClinicalEffectOnAlzheimersDisease, neutral]
-
A.
hasPharmacologicalEffect
Indicates that one entity produces a specific pharmacological effect or action on another entity.
-
B.
isNeuroprotective
Indicates that one entity confers protection to another entity’s nervous system or neural structures, helping to prevent or reduce neural damage or degeneration.
-
C.
hasClinicalSignificance
chosen
Indicates that something (such as a finding, variant, or condition) has a meaningful impact or relevance in a clinical or medical context.
-
D.
hasCommonAdverseEffect
Indicates that two or more entities share at least one adverse effect that occurs in response to them.
-
E.
potentialTherapeuticUse
Indicates that something is being considered or investigated as a possible treatment or therapy for a condition or disease.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69da626a67648190af9653832a3aeced |
completed | April 11, 2026, 3:02 p.m. |
| NER | Named-entity recognition | batch_69e65fe10ffc81908c94168b0a8ea9c9 |
completed | April 20, 2026, 5:18 p.m. |
| PD | Predicate disambiguation | batch_69e537fd311881908448f2aea8b4812e |
completed | April 19, 2026, 8:15 p.m. |
Created at: April 11, 2026, 3:31 p.m.